Canaan Inc. Files 2025 Annual Report on Form 20-F

Canaan Inc. (NASDAQ: CAN) ("Canaan" or the "Company"), an innovator in crypto mining, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission on April 15, 2026. The annual report CAN be accessed on the SEC's website at http:www.sec.gov and on the Company's investor relations website at https:investor.canaan-creative.com.

The Company will provide a hard copy of the annual report, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to the Company's Investor Relations Department at IR@canaan-creative.com.

About Canaan Inc.

Established in 2013, Canaan Inc. (NASDAQ: CAN), is a technology company focusing on ASIC high-performance computing chip design, chip research and development, computing equipment production, and software services. Canaan has extensive experience in chip design and streamlined production in the ASIC field. In 2013, Canaan's founding team shipped to its customers the world's first batch of mining machines incorporating ASIC technology under the brand name Avalon. In 2019, Canaan completed its initial public offering on the Nasdaq Global Market. To learn more about Canaan, please visit https://www.canaan.io/.

Investor Relations Contact

Canaan Inc.
Xi Zhang
Email: IR@canaan-creative.com

Christensen Advisory
Christian Arnell
Email: canaan@christensencomms.com

Public Relations Contact

BlocksBridge Consulting
Jesse Colzani
Email: canaan@blocksbridge.com

 

Cision View original content:https://www.prnewswire.com/news-releases/canaan-inc-files-2025-annual-report-on-form-20-f-302743793.html

SOURCE Canaan Inc.

News Provided by PR Newswire via QuoteMedia

CAN
The Conversation (0)
Nuvau Winter Drilling at Thundermine Returns 5.28 g/t Au over 6.1 m, Including 7.22 g/t Au over 3.1 m

Nuvau Winter Drilling at Thundermine Returns 5.28 g/t Au over 6.1 m, Including 7.22 g/t Au over 3.1 m

Results suggestive of a gold-bearing hydrothermal system and multiple mineralization styles in a largely underexplored target area Nuvau Minerals Inc. (TSXV: NMC,OTC:NMCPF) reports encouraging results from its winter drilling campaign at the Thundermine (also called Thunderwood) target area in... Keep Reading...
Premier American Uranium Reports Results Following Annual General and Special Meeting of Shareholders

Premier American Uranium Reports Results Following Annual General and Special Meeting of Shareholders

Premier American Uranium Inc. ("PUR", the "Company" or "Premier American Uranium") (TSXV: PUR,OTC:PAUIF) (OTCQB: PAUIF) is pleased to report that all matters presented at the annual general and special meeting of shareholders (the "Meeting"), held today, were approved by shareholders, as... Keep Reading...
New Found Gold Announces Results of 2026 Annual General Meeting

New Found Gold Announces Results of 2026 Annual General Meeting

Hires ICP as Market MakerNew Found Gold Corp. (TSXV: NFG) (NYSE American: NFGC) ("New Found Gold" or the "Company") is pleased to announce the results of the 2026 Annual General Meeting of its shareholders held in Toronto, ON, on June 25, 2026 (the "Meeting"). The Company's Board of Directors... Keep Reading...
Steadright Cancels Purchase of 80% Interest in Moroccan Antimony Company

Steadright Cancels Purchase of 80% Interest in Moroccan Antimony Company

(TheNewswire) June 25, 2026 TheNewswire - Muskoka, Ontario Steadright Critical Minerals Inc. (CSE: SCM,OTC:SCMNF) ("Steadright" or the "Company") announces that it has terminated, effective immediately, the previously announced agreement dated June 9, 2026, to acquire 80% of the outstanding... Keep Reading...
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral... Keep Reading...

Interactive Chart

Latest Press Releases

Related News